
Carl Zeiss Meditec AG
CZMWF
Updated: 24/09/2026, 18:14:51
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
No summaries found.
- Share price
- $37.41
- Market cap
- $3.27B
- Exchange
- OTC
- Currency
- USD
- CEO
- Andreas Pecher
- Employees
- 5,784
- IPO date
- 14/03/2012
- Beta
- 1.394
- Last dividend
- $0.00
- Day range
- $32.76 – $37.41
- 52-week range
- $26.42 – $55.75
- 1-day performance
- 15.64%
- 1-year performance
- 41.60%
- Current drawdown (1Y)
- -32.90%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- DE0005313704
- Created
- 07/12/2025, 03:32:13
- Last update
- 24/09/2026, 18:14:51
Track Carl Zeiss Meditec AG with an AI analyst
See which prediction-market events move CZMWF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.